Commentary
Given the growing importance of NAFLD and its inflammatory manifestation, in a new prospective study from the NASH Clinical Research Network, A. J. Sanyal et al. describe outcomes for 1773 adults with biopsy-proven NAFLD with an average follow-up period of 4 years.
At baseline, 25% of patients had NAFLD without NASH, and 75% had borderline or definite NASH. During follow-up, mortality and incidence of hepatic decompensation events were progressively higher across fibrosis stage at baseline. Fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death.
